王杭祥
查看科室更多醫(yī)生性 別：男
最高學(xué)歷,、學(xué)位：研究生、博士
職 稱：研究員
個(gè)人簡介
博士生導(dǎo)師,，課題組長。長期從事生物材料及技術(shù)用于惡性腫瘤治療研究，包括腫瘤智能藥物遞送新技術(shù)和創(chuàng)新制劑的研發(fā)，并重點(diǎn)圍繞抗腫瘤原創(chuàng)藥物的合成,、納米藥物制劑化及應(yīng)用等領(lǐng)域開展研究工作，創(chuàng)建了獨(dú)具個(gè)人研究特色的前藥策略,，取得了一系列重要的原創(chuàng)性科研成果，已在J. Am. Chem. Soc.,、Angew. Chem. Int. Ed.,、Cancer Res.、Nano Today,、Adv. Funct. Mater.,、J. Controlled Release、Nucleic Acids Res.,、ACS Nano 等高水平學(xué)術(shù)期刊以第一或通訊作者發(fā)表研究論文60多篇,。以第一發(fā)明人獲得15 項(xiàng)中國發(fā)明專利授權(quán)。作為項(xiàng)目負(fù)責(zé)人獲得3項(xiàng)國家自然科學(xué)基金面上項(xiàng)目和1項(xiàng)青年項(xiàng)目,，并獲得2018年浙江省自然科學(xué)基金杰出青年項(xiàng)目的資助,。
專業(yè)擅長
針對(duì)惡性腫瘤及各種臨床疾病設(shè)計(jì)合成藥物及納米制劑。
研究方向
主要聚焦于肝膽胰疾病的藥物治療研究,，抗癌創(chuàng)新藥物,、納米藥物遞送以及抗癌分子機(jī)制的研究。
成果獎(jiǎng)項(xiàng)：（近五年主要成果及獎(jiǎng)勵(lì)情況）
近五年代表論文：
1) Quantitative Self-Assembly of Photoactivatable Small Molecular Prodrug Cocktails for Safe and Potent Cancer Chemo-Photodynamic Therapy, L. Huang, J. Wan, H. Wu, X. Chen, Q. Bian, L. Shi, X. Jiang, A. Yuan, J. Gao*, and H. Wang*, Nano Today, 2021, 36, 101030.
2) 2) Self-assembling a natural small molecular inhibitor that shows aggregation-induced emission and potentiates antitumor efficacy, X. Chen, Z. Hu, L. Zhou, F. Zhang, J. Wan, and H. Wang*, Nanoscale Horizons, 2021, 6, 33-42.
3) Structure-Guided Engineering of Cytotoxic Cabazitaxel for an Adaptive Nanoparticle Formulation: Enhancing the Drug Safety and Therapeutic Efficacy, J. Wan, Y. Qiao, X. Chen, J. Wu, L. Zhou, J. Zhang, S. Fang and H. Wang*, Adv. Funct. Mater., 2018, 28, 1804229.
4) Self-assembling prodrugs by precise programming of molecular structures that contribute distinct stability, pharmacokinetics, and antitumor efficacy, H. Wang, H. Xie, J. Wang, J. Wu, X. Ma, L. Li, X. Wei, Q. Ling, P. Song, L. Zhou, X. Xu,* and S. Zheng*, Adv. Funct. Mater., 2015, 25, 4956-4965.
5) New Generation Nanomedicines Constructed from Self-Assembling Small Molecule Prodrugs Alleviate Cancer Drug Toxicity, H. Wang*, Z. Lu, L. Wang, T. Guo, J. Wu, Z. Li, D. Jiang, P. Song, H. Xie, L. Zhou, X. Xu and S. Zheng*, Cancer Res., 2017, 77, 6963-6974.
6) Design and fabrication of conductive polymer hydrogels and their applications in flexible supercapacitors, X Han, G. Xiao*, Y. Wang, X. Chen, G. Duan, Y. Wu, X. Gong*, and H. Wang*, J. Mater. Chem. A, 2020, 8, 23059-23095.
7) Quantum dots-based hydrogels for sensing applications, J. Zhang, J. Jin, J. Wan, S. Jiang, W. Wang, X. Gong*, and H. Wang*, Chemical Engineering Journal, 2021, 408, 127351.
8) Target-Oriented Delivery of Self-Assembled Immunosuppressant Cocktails Prolongs Allogeneic Orthotopic Liver Transplant Survival, H. Xie,# H. Zhu,# K. Zhou, J. Wan, L. Zhang, Z. Yang, L. Zhou, X. Chen, X. Xu, S. Zheng,* and H. Wang*, J. Controlled Release, 2020, 328, 237-250.
9) Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts, L. Shi, Y. Wang, Q. Wang, Z. Jiang, L. Ren, Y. Yan, Z. Liu, J. Wan, L. Huang, B. Cen, W. Han*, and H. Wang*, J. Controlled Release, 2020, 324, 289-302.
10) Photosensitizer-stabilized self-assembling nanoparticles potentiate chemo/photodynamic efficacy of patient-derived melanoma, L. Huang, X. Chen, Q. Bian, F. Zhang, H. Wu, H. Wang*, and J. Gao*, J. Controlled Release, 2020, 328, 325-338.
11) Structure-based rational design of prodrugs to enable their combination with polymeric nanoparticle delivery Platforms for enhanced antitumor efficacy, H. Wang*, H. Xie, J. Wu, X. Wei, L. Zhou, X. Xu,* and S. Zheng*, Angew. Chem. Int. Ed., 2014, 53, 11532-11537.
12) Self-assembling myristoylated human alpha-defensin 5 as a next-generation nanobiotics potentiates therapeutic efficacy in bacterial infection, R. Lei, J. Hou, Q. Chen, W. Yuan, B. Cheng, Y. Sun, Y. Jin, L. Ge, S. A. Ben-Sasson, H. Wang*, W. Lu*, X. Fang*, ACS Nano, 2018, 12, 5284-5296.
13) ZNF830 Mediates Cancer Chemoresistance through Promoting Homologous-Recombination Repair, G. Chen*, J. Chen, Y. Qiao, Y. Shi, W. Liu, Q. Zeng, X. Shi, Y. Sun, X. Liu, T. Li, L. Zhou, J. Wan, H. Wang* and F. Wang*, Nucleic Acids Res., 2018, 46, 1266-1279.
14) A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer, W. Han, L. Shi, T. Li, L. Zhou, L. Ren, Y. Qiao and H. Wang*, Signal Transduction and Targeted Therapy, 2018, 3, 16.
15) Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer, W. Han*, B. Xie, Y. Li, L. Shi, J. Wan, X. Chen and H. Wang*, Theranostics, 2019, 9, 7458-7473.
16) Polylactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinoma, H. Wang*, L. Zhou, K. Xie, J. Wu, P. Song, H. Xie, L. Zhou, J. Liu, X. Xu, Y. Shen and S. Zheng*, Theranostics, 2018, 8, 3949-3963.
17) Cancer Nanomedicines Stabilized by π-π Stacking between Heterodimeric Prodrugs Enable Exceptionally High Drug Loading Capacity and Safer Delivery of Drug Combinations, H. Wang*, J. Chen, C. Xu, M. Tayier, J. Zhou, J. Zhang, J. Wu, Z. Ye, T. Fang, W. Han*, Theranostics, 2017, 7, 3638-3652.
18) Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma, L. Wu, F. Zhang, X. Chen, J. Wan, Y. Wang, T. Li, and H. Wang*, ACS Applied Materials & Interfaces, 2020, 12, 3327-3340.
19) Supramolecular Engineering of Molecular Inhibitors in an Adaptive Cytotoxic Nanoparticle for Synergistic Cancer Therapy, W. Han*, L. Shi, B. Xie, J. Wan, L. Ren, Y. Wang, X. Chen and H. Wang*, ACS Applied Materials & Interfaces, 2020, 12, 1707-1720.
20) Precise Engineering of Prodrug Cocktails into Single Polymeric Nanoparticles for Combination Cancer Therapy: Extented and Sequentially Controllable Drug Release, H. Wang*, J. Wu, K. Xie, T. Fang*, C. Chen, H. Xie. L. Zhou, and S. Zheng*, ACS App. Mater. & Interfaces, 2017, 9, 10567-10576.
21) Dimerization-Induced Self-Assembly of a Redox-Responsive Prodrug into Nanoparticles for Improved Therapeutic Index, L. Zhou, H. Xie, X. Chen, J. Wan, S. Xu, Y. Han, D. Chen, Y. Qiao, L. Zhou, S. Zheng*, and H. Wang*, Acta Biomaterialia, 2020, 113, 464-477.
22) Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies, B. Xie, J. Wan, X. Chen, W. Han* and H. Wang*, Mol. Cancer Ther., 2020, 19, 822-834.
社會(huì)任職
擔(dān)任浙江省藥學(xué)會(huì)生物制藥專業(yè)委員會(huì)青年分委會(huì)副主任委員
SCI期刊Chinese Chemical Letters的青年編委
